Ingenia Therapeutics Inc. (KOSDAQ:950260)
South Korea · Delayed Price · Currency is KRW 18,000
+650 (3.75%)
At close: Aug 28, 2026
Ingenia Therapeutics Statistics
Total Valuation
KOSDAQ:950260 has a market cap or net worth of KRW 890.00 billion. The enterprise value is 882.80 billion.
| Market Cap | 890.00B |
| Enterprise Value | 882.80B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
KOSDAQ:950260 has 49.44 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 49.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +220.85% |
| Owned by Insiders (%) | 26.32% |
| Owned by Institutions (%) | 2.86% |
| Float | 11.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 65.25 |
| P/TBV Ratio | 68.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.44 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -186.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -786.00% |
| Return on Capital Employed (ROCE) | -231.39% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.34B |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.16B |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 19,120,487 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.37B |
| Pretax Income | -28.97B |
| Net Income | -26.81B |
| EBITDA | -32.29B |
| EBIT | -33.37B |
| Earnings Per Share (EPS) | -1,289.44 |
Balance Sheet
The company has 8.90 billion in cash and 1.69 billion in debt, with a net cash position of 7.21 billion or 145.75 per share.
| Cash & Cash Equivalents | 8.90B |
| Total Debt | 1.69B |
| Net Cash | 7.21B |
| Net Cash Per Share | 145.75 |
| Equity (Book Value) | 13.64B |
| Book Value Per Share | 308.67 |
| Working Capital | 3.73B |
Cash Flow
In the last 12 months, operating cash flow was -32.86 billion and capital expenditures -954.20 million, giving a free cash flow of -33.81 billion.
| Operating Cash Flow | -32.86B |
| Capital Expenditures | -954.20M |
| Depreciation & Amortization | 1.09B |
| Net Borrowing | -792.34M |
| Free Cash Flow | -33.81B |
| FCF Per Share | -683.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KOSDAQ:950260 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.01% |
| FCF Yield | -3.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |